2019 LIVER Symposium
This event has now passed.
The Northern California Society for Clinical Gastroenterology (NCSCG) is pleased to open registration for the 2019 Liver Symposium (formerly known as the Post-AASLD Symposium) being held Saturday, December 7, 2019, at the Hyatt Regency in San Francisco, CA.
The symposium will provide a unique opportunity for attendees to receive a comprehensive update on chronic liver disease from nationally renowned faculty. The educational lectures at the symposium will focus on important advances presented at the annual meeting of the American Association for the Study of Liver Disease (AASLD) and/or recent publications. The NCSCG is excited to incorporate a new, engaging and interactive point-counterpoint format this year which will feature expert faculty presenters exploring current controversies in the management of patients with liver disease, along with traditional style sessions. You will also have ample opportunity to interact with colleagues, our expert faculty members, and industry representatives.
Please mark your calendar to attend this exciting symposium. Complete conference and registration information will be available in September. Please feel free to contact the NCSCG with any questions or inquiries by sending an email to firstname.lastname@example.org
The NCSCG Board
Erick Chan, MD; President
Radhika Kumari, MD; Vice President
Edward W. Holt, MD; Treasurer
Suraj Gupta, MD; Secretary
Bilal Hameed, MD; Board Member
Eric Mao, MD; Board Member
Marina Roytman, MD; Board member
Neil Stollman, MD; Board Member
Robert Wong, MD, MS; Board Member
Allied Healthcare Professional $28
Fellow - Complimentary
Allied Healthcare Professional $77
Additional Industry Representative $275
To become an NCSCG member or renew your membership click here
This activity has been designed to meet the educational needs of physicians, physician assistants and nurse practitioners involved in the care of patients with chronic liver disease (CLD).
Statement of Need
The goal of this program is to provide important clinical and scientific data on the management of chronic liver disease (CLD).
Upon completion of this symposium, participants should be better able to:
Describe current guidelines for the treatment and management of patients with liver disease
Optimize treatment results for patients with liver disease, through utilizing new therapies
Identify new advances presented at AASLD 2019 and assess their potential impact on clinical practice
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of the Rehoboth McKinley Christian Health Care Services (RMCHCS) and the Northern California Society for Clinical Gastroenterology. RMCHCS is accredited by NMMS to provide continuing medical education for physicians.
RMCHCS designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
New this year!
Successful completion of this CME activity enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
Participants will be able to locate MOC information on this ACCME website
To View the Sponsors of the 2019 LIVER Symposium
This activity is supported by an educational grant from Gilead Sciences, Inc., Mallinckrodt Pharmaceuticals, Pentax of America, Salix Pharmaceuticals and Takeda Pharmaceuticals U.S.A